In this study, researchers used a Mendelian randomization approach based on a genetic score for serum CETP concentration (rs247616, rs12720922 and rs1968905) to estimate causal effects per unit (µg/mL) increase in CETP on standardized metabolic biomarkers, primarily lipoprotein subclasses.

Higher CETP concentrations were associated with less large HDL and more small VLDL components. No causal effects were observed with LDL subclasses. The results show that CETP is an important causal determinant of HDL and VLDL concentration and composition. Also, the results imply that the CETP inhibitor anacetrapib decreased CVD risk through specific reduction of small VLDL rather than LDL.